{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:21:23Z","timestamp":1788448883565,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01616-6","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:53:13Z","timestamp":1788447193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2981-3689","authenticated-orcid":false,"given":"Ricardo","family":"Ahrens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Al-Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"Lisa","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-025-04175-8","volume":"32","author":"H Lee","year":"2026","unstructured":"Lee H, Ahn S, Gonzales GA, Leblay N, Barakat E, Greening D, et al. Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma. Nat Med. 2026;32:964\u201377.","journal-title":"Nat Med"},{"key":"1616_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354.","journal-title":"Leukemia"},{"key":"1616_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70260","volume":"9","author":"NWCJ van de Donk","year":"2025","unstructured":"van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos M-V, Dimopoulos MA, Zweegman S, et al. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network. HemaSphere. 2025;9:e70260.","journal-title":"HemaSphere"},{"key":"1616_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1616_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","volume":"145","author":"J Eckmann","year":"2025","unstructured":"Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. 2025;145:202\u201319.","journal-title":"Blood"},{"key":"1616_CR6","doi-asserted-by":"publisher","first-page":"168748","DOI":"10.1016\/j.jmb.2024.168748","volume":"436","author":"J Jeong","year":"2024","unstructured":"Jeong J, Park J, Young Mo G, Shin J, Cho Y. Structural basis for the recognition of GPRC5D by talquetamab, a bispecific antibody for multiple myeloma. J Mol Biol. 2024;436:168748.","journal-title":"J Mol Biol"},{"key":"1616_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49625-y","volume":"15","author":"P Yan","year":"2024","unstructured":"Yan P, Lin X, Wu L, Xu L, Li F, Liu J, et al. The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer. Nat Commun. 2024;15:5255.","journal-title":"Nat Commun"},{"key":"1616_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/bioinformatics\/bty635","volume":"35","author":"J Jankauskait\u0117","year":"2019","unstructured":"Jankauskait\u0117 J, Jim\u00e9nez-Garc\u00eda B, Dapk\u016bnas J, Fern\u00e1ndez-Recio J, Moal IH. SKEMPI 2.0: an updated benchmark of changes in protein\u2013protein binding energy, kinetics and thermodynamics upon mutation. Bioinformatics. 2019;35:462\u20139.","journal-title":"Bioinformatics"},{"key":"1616_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"1616_CR10","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4:1536\u201343.","journal-title":"Nat Cancer"},{"key":"1616_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO-24-01785","volume":"43","author":"EM Jurgens","year":"2025","unstructured":"Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, et al. Phase I trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for multiple myeloma: updated analysis. J Clin Oncol. 2025;43:498\u2013504.","journal-title":"J Clin Oncol"},{"key":"1616_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025030027","volume":"147","author":"K Pillarisetti","year":"2026","unstructured":"Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, et al. Ramantamig (JNJ-79635322), a T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Blood. 2026;147:834\u201347.","journal-title":"Blood"},{"key":"1616_CR13","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","volume":"43(16_supp)","author":"NWCJ van de Donk","year":"2025","unstructured":"van de Donk NWCJ, Vega G, Perrot A, Anguille S, Oriol A, Minnema M, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody, in patients with relapsed\/refractory multiple myeloma: initial phase 1 results. J Clin Oncol. 2025;43:7505.","journal-title":"J Clin Oncol"},{"key":"1616_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"1616_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41375-026-02889-3","volume":"40","author":"C Riedhammer","year":"2026","unstructured":"Riedhammer C, Truger M, Lee H, Leypoldt LB, Meggendorfer M, Hutter S, et al. The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D. Leukemia. 2026;40:730\u20138.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01616-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:53:13Z","timestamp":1788447193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01616-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RA reports travel support from Amgen, Sanofi, BeOne and Pfizer and served as a consultant for Stemline and Pfizer. KA declares no competing interests. MA-B reports travel support from Stemline. LL reports travel support from Sanofi, Oncopeptides, J&J and Amgen, served as a consultant for GSK, Sanofi, J&J and Pfizer, received honoraria from Adaptive, Amgen, AbbVie, J&J, Pfizer, Sanofi, Regeneron, Takeda and AstraZeneca and received research funding from AbbVie, GSK (both to the institution) and Amgen. CB received honoraria from AOK Germany, AstraZeneca, Bayer, Berlin Chemie, Bristol Myers Squibb, GSO Research Organisation, J&J, med update, Merck Serono, MSD, Novartis, Roche and Sanofi. WA has received travel grants from J&J, Immatics and BioNTech, honoraria from GSK, Astellas, Janssen and AstraZeneca and research funding (to the institution) from Affimed and BioNTech. KW served as a consultant for AbbVie, Adaptive Biotech, Amgen, BeOne, GSK, J&J, Karyopharm, Stemline, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, and Takeda and received honoraria from AbbVie, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Celgene, GSK, J&J, Novartis, Oncopeptides, Sanofi, Stemline, and Takeda and served on the Board of Directors or advisory committees for AbbVie, Adaptive Biotech, Amgen, BeOne, Bristol Myers Squibb, Celgene, GSK, J&J, Karyopharm, Stemline, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, and Takeda and received research funding from AbbVie, Amgen, GSK, J&J, Pfizer, Bristol Myers Squibb, Novartis, Sanofi, and Takeda.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"146"}}